Précédent
Suivant
Improving the quality of life and performance of animals and humans through biotherapies that respect the environment and animal welfare.
Vetbiobank develops and manufactures innovative, practical and widely available veterinary biotherapies to treat chronic inflammatory or immune animal diseases related to age or trauma.
Industrial and multi-species manufacturing of neonatal stem cells and clinical development in compliance with Good Manufacturing Practices (GMP) and Good Clinical Practices (GCP).
Vetbiobank has a unique industrial and clinical know-how in regenerative veterinary medicine.
Vetbiobank offers major players in the veterinary and human pharmaceutical industry a pipeline of innovative therapies at various stages of clinical validation, from proof of concept to marketing authorization, to ensure their availability to the largest number of prescribers and patients.
After developing a proprietary and fully integrated manufacturing process for neonatal mesenchymal stem cells at its R&D site in Marcy l'Etoile, we opened a GMP-certified pharmaceutical facility in Lyon (France) for the industrial bioproduction of clinical grade therapeutic cells.
Our flagship product targeting the canine osteoarthritis market, which is worth 1.9 billion euros. It is entering its final phase of clinical development in view of obtaining European marketing authorization from the EMA. It will then be marketed by a renowned industrial partner belonging to the top 10 in the veterinary pharmaceutical industry under an exclusive partnership.
Our pipeline includes other developments such as canine atopic dermatitis and feline gingivostomatitis which are currently being offered to other industrial partners who, in both veterinary and human medicine, are eager to find new growth areas and who see cell therapy as tomorrow's therapeutics.
Vetbiobank relies on strategic collaborations to complete the clinical validation of its products and to meet the industrial challenges of cell therapy, i.e. to produce on a large scale while reducing the cost of treatment, thus making them accessible to the greatest number.
As a pioneer and key player in veterinary cell therapy, Vetbiobank aims to be the leading partner of the pharmaceutical industry in veterinary and human health for the development and production of drugs for new or innovative therapies.
Thanks to its research and development work, Vetbiobank has succeeded in developing "universal" treatments whose safety and efficacy have been scientifically proven B, C, E and are financially accessible to animal owners.
First French Pharmaceutical company Manufacturer Establishment in Cellular Therapy
In November 2019 Vetbiobank obtained the opening authorization No. V240633/19 from its Veterinary Pharmaceutical Establishment for the manufacture of veterinary drugs undergoing clinical trials.
In April 2021, Vetbiobank is the first French laboratory to obtain the Good Manufacturing Practices (GMP) certification for its veterinary cell therapy drugs (certificate n°21/291457).
Limiting the release of bioactive molecules or chemicals into the environment: logistics/storage/manufacturing to limit the use of fossil fuels (plastic; fuel; LN2)
Vetbiobank has made the ethical choice to work with neonatal stem cells collected from placentas at birth. We recover neonatal tissues considered as biological waste and expelled during childbirth.
Unlike fat or blood tissue samples, the collections are carried out without any invasive medical procedure when giving birth to puppies, foals, kittens, etc...
CEO & Founder
COO Business Development
Head of Biomanufacturing and Chief Quality Officer
Chercheur en R&D - Responsable de la Propriété Industrielle
Chargée de mission Management des Risques et de la Qualité
Administrative and Customer Service Manager
Focus on regenerative veterinary medicine
While in the United States, veterinary regenerative medicine is developing with techniques based on the use of autologous bone marrow or fat cells (at prohibitive costs, then reserved for a restricted group of owners), Stéphane Maddens anticipates the major interest that the use neonatal stem cells in animal health would represent. An entrepreneurial project was then born in his mind.
Business and managerial skills
To embark on this adventure, he decided to complete his scientific background with an MBA "Change and Innovation", delivered by the IAE of Aix en Provence. There, with the help of a group of friends, he validates the market opportunity that this breakthrough innovation represents.
Vetbiobank's inception
In 2010, he obtained the support of VetAgro-Sup, the Veterinary School of Lyon, and after having successfully developed the first neonatal equine cell bank, he founded Vetbiobanka BANK of BIOlogical VETerinary products.
He then demonstrated the safety and efficacy of these cells in competition horses, and the objective became realistic: to market the first veterinary drug based on neonatal stem cells for the treatment of canine osteoarthritis that is manufactured on an industrial scale to allow its use by the largest number of owners.
The company's growth and expansion in canine osteoarthritis
It was then time for Stéphane to raise funds from business angels and public institutions to enable him to gradually surround himself with a team of passionate scientists who managed to adapt the technology from the horse to the dog, 1 in 5 of whom in the world suffers from osteoarthritis.
The company's future prospects
Eventually, Vetbiobank will capitalize on the development of this veterinary drug to tackle human osteoarthritis, a real public health scourge that is still without a satisfactory solution today. The data acquired in dogs, one of the best models for human osteoarthritis, will enable Vetbiobank to considerably reduce the risk and duration of clinical development in humans. Vetbiobank wants to be a recognized player among the first to bring to market a safe and effective treatment for human osteoarthritis based on neonatal stem cells that is acceptable to most public healthcare systems worldwide.
Company
Technologies
Products
Partners
News
© 2021 Vetbiobank All Rights Reserved